RxDoctor Payments Data

Jaclyn Jezak

Psychiatric/Mental Health · Fremont, OHNPI 1922764760

Payments from drug & device makers

$4,023in general payments, 2019–2025

Across 162 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$671
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$466
  • Alkermes, Inc.$422
  • Ironshore Pharmaceuticals Inc.$308
  • GSK$250
  • Otsuka America Pharmaceutical, Inc.$231
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$3,96298%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,023 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$10,133
Medicare patients
25
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$20,931
Paliperidone ErPaliperidone28$8,883
AzstarysSerdexmethylphen/Dexmethylphen11$4,196
Duloxetine Hcl53$1,108
Bupropion XlBupropion Hcl42$762
Aripiprazole25$716
Buspirone Hcl60$701
Hydroxyzine Hcl37$683
Fluoxetine Hcl58$671
Sertraline Hcl112$598
Lamotrigine54$497
Escitalopram Oxalate48$463
Mirtazapine35$450
Trazodone Hcl52$413
Amitriptyline Hcl29$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$231$20,93114 claims
Corium, LLCAzstarys$114$4,19611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Fremont

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →